As previously reported, Raymond James analyst Danielle Brill upgraded Disc Medicine (IRON) to Strong Buy from Outperform with a price target of $110, up from $66, after the company announced that its its end-of-Phase 2 meeting with the FDA for bitopertin in erythropoietic porphyrias, or EPP resulted in agreement on all proposed attributes of the APOLLO study. The “uber bull case scenario played out” as the FDA is amenable to an accelerated approval filing using PPIX reduction as a surrogate biomarker of efficacy, which allows Disc to file using the data generated-to-date, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine upgraded to Strong Buy from Outperform at Raymond James
- Disc Medicine Gains FDA Support for Bitopertin Trial
- Disc Medicine announces feedback from FDA End of Phase 2 meeting for bitopertin
- Disc Medicine Reports Promising Phase 1b Trial Results
- Disc Medicine appoints Kaushik as Chief Technical Officer